Amyloid is an abnormal protein that can build up in various organs and tissues of the body, causing a rare disease called amyloidosis. While there is not a cure for amyloidosis, there are treatments to help control the production of amyloid in the body.

The Amyloid Treatment and Research Program is dedicated to the evaluation and care of patients with all forms of localized and systemic amyloidoses. The Amyloid Program is also a leader in molecular, cellular, and biophysical investigations of protein misfolding and amyloid fibril formation.

Founded in 1960, BMC's nationally recognized Amyloid Program is staffed by a multidisciplinary team of clinicians from Nephrology, Neurology, Cardiology, Endocrinology, Hematology, Gastroenterology, and Pulmonary/Critical Care Medicine. Each year, over 300 patients from around the world undergo a 3-day evaluation through the Amyloid Clinic to clarify and define disease phenotypes so that a rational and effective treatment plan can be developed. Learn more about the Amyloid Treatment and Research Program.